Add as a preferred source on GoogleXencor Shares Climb 23.94% on XmAb819 Kidney Cancer Results
A Phase 1 study showed a 45.5% response rate in advanced kidney cancer. Xencor plans accelerated discussions with the Food and Drug Administration.
Xencor shares rose 23.94% Monday, Oct. 26, after results from a Phase 1 trial of XmAb819 showed a 45.5% response rate in advanced kidney cancer.
XmAb819 is a drug studied for advanced kidney cancer. Xencor plans accelerated discussions with the Food and Drug Administration (FDA).
The broader U.S. market backdrop was mixed: futures steadied Monday morning after two consecutive weekly declines in major indexes. Oil prices remained elevated, and skepticism over AI capital spending persisted.
Enna Lee
ReporterEnna Lee reports on investing and digital-asset markets for TokenPost. Send corrections or tips to info@tokenpost.com.